Old Web
English
Sign In
Acemap
>
authorDetail
>
B. Stollenwerk
B. Stollenwerk
Amgen
Osteoporosis
Medicine
cost effectiveness
Population
Relative risk
3
Papers
8
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan.
2021
Osteoporosis International
H. Hagino
Kiyoshi Tanaka
S Silverman
Michael R. McClung
Shravanthi R. Gandra
M. Charokopou
K. Adachi
B. Johnson
B. Stollenwerk
Show All
Source
Cite
Save
Citations (1)
A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis.
2021
Osteoporosis International
E. Söreskog
F. Borgström
I Lindberg
Oskar Ström
D. Willems
Cesar Libanati
J A Kanis
B. Stollenwerk
Mata Charokopou
Show All
Source
Cite
Save
Citations (1)
Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom
2019
Osteoporosis International
A Svedbom
P. Hadji
E. Hernlund
R. Thoren
Eugene McCloskey
R. Stad
B. Stollenwerk
Show All
Source
Cite
Save
Citations (6)
1